Changing Compliance to Change the Game: IVL for Transfemoral EVAR/TEVAR Access

Frank Arko, MD, Chief of Vascular and Endovascular Surgery, Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina

Video

Changing Compliance to Change the Game: IVL for Transfemoral EVAR/TEVAR Access

Frank Arko, III, MD

Keywords

intravascular lithotripsy

EVAR

TEVAR

August 2022

ISSN 2152-4343

In this interview, Frank Arko, MD, Chief of Vascular and Endovascular Surgery at Sanger Heart and Vascular Institute, Atrium Health discusses his use of IVL to maintain transfemoral EVAR/TEVAR access in patients with calcified vessels. Dr. Arko reviews the Shockwave PAD III RCT data including recently published 1- and 2-year results, as well as the results of the Shockwave PAD OS iliac cohort. Dr. Arko then shares a case example of how IVL allowed him to use transfemoral access in a patient with calcified iliac and CFA disease.

Stay in the Know

Vascular Disease Management Newsletter

News

Late-Breaking Trials

Second Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/04/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the second of four rounds of Late-Breaking Clinical Trials...

The VIVA Foundation, a...

11/04/2024

Vascular Disease Management

Late-Breaking Trials

First Round of Late-Breaking Clinical Trial Results Announced at VIVA24

11/04/2024

The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first of four rounds of Late-Breaking Clinical Trials...

The VIVA Foundation, a...

11/04/2024

Vascular Disease Management

Image-Guided Therapy

Philips Enrolls First Patient in U.S. Clinical Trial for Innovative Integrated Single-Device to Treat Peripheral Artery Disease

11/04/2024

With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD) Cardiovascular...

With a unique world-first...

11/04/2024

Vascular Disease Management

Pulmonary Embolism

Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism

11/04/2024

QUADRA-PE study will evaluate the safety and effectiveness of the Katana™ Thrombectomy System LOS GATOS, Calif., Nov. 4, 2024 /PRNewswire/ -- Akura Medical, a Shifamed portfolio company focused on reshaping the...

QUADRA-PE study will evaluate...

11/04/2024

Vascular Disease Management

Peripheral Arterial Disease

FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease

11/04/2024

MOUNTAIN VIEW, Calif. – November 4, 2024 – R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce...

MOUNTAIN VIEW, Calif. – November...

11/04/2024

Vascular Disease Management

Patient Awareness

Baby Boomers Beware: More Americans Than Ever Before Now at Higher Risk for Common Blood Vessel Diseases

10/31/2024

New survey reveals nearly one in three Americans at highest risk for blood vessel diseases and life-threatening complications report low awareness Society for Vascular Surgery launches the Highway to Health campaign to help people maintain...

New survey reveals nearly one in...

10/31/2024

Vascular Disease Management

DCB

SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery

10/30/2024

Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...

Data from the prospective,...

10/30/2024

Cath Lab Digest

Zilver Vena Stent

Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study

10/29/2024

Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...

Bloomington, Ind. — Cook...

10/29/2024

Vascular Disease Management

Pulmonary Embolism

TCT: RESCUE II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis Without Post-Procedure Infusion in Treating Acute Pulmonary Embolism

10/28/2024

The BASHIR™ Endovascular Catheter was used to deliver 4mg of recombinant tissue plasminogen activator (r-tPA) into each pulmonary artery (PA). The study showed that the independent core laboratory assessed primary endpoint of the right...

The BASHIR™ Endovascular...

10/28/2024

Cath Lab Digest

meeting update

Inaugural Global Symposium on Interventional Radiation Protection to Focus on Keeping Lab-Based Clinicians Safe

10/28/2024

HMP Global, in partnership with Occupational Radiation Safety in Interventional Fluoroscopy (ORSIF), will host the first-of-its-kind Global Symposium on Interventional Radiation Protection (SIRP), to be held September 26-27, 2025.

HMP Global, in partnership with...

10/28/2024

EP Lab Digest

Changing Compliance to Change the Game: IVL for Transfemoral EVAR/TEVAR Access

Stay in the Know

News

Specialties

Events

Year Round Education

HMP Global Products